Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3120 + EV + Pembrolizumab in First-Line Advanced Urothelial Carcinoma
NCT07232602Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Primary completion
- Jul 2031
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
A Phase 2 trial of MK-3120 in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Feb 2026; status: recruiting.
02
Drugs
MK-3120
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07232602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232602.